		ICIVIJE DISCE	OSURE FORIVI
Date	e:2022/4/2	7	
You	r Name: Aiheta	aimuiiang Anwaier	
Mar met	nuscript Title: Real-Woi	ld data on the efficacy an A Multicenter Retrospect	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
to ti med In it	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		ICIVISE DISCE	SOME I GIMI
Date	e:2022/4/2	7	
You	r Name: Jianhu	ıi Chen	
Mar	nuscript Title: Real-Wor	ld data on the efficacy an	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the current
to ti med In it	he epidemiology of hyperter dication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other item
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article		
	processing charges, etc.)		-
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		icivise bisce	SOME I OMIVI
Date	e:2022/4/2	7	
You	e:2022/4/2 r Name: Hongf	eng Zhou	
Mar	nuscript Title: Real-Wor	ld data on the efficacy an	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):		
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the properties of the manuscript. If you are in doubt about whether to list a so.
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th med In it	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported the past 36 months.	d in this manuscript without time limit. For all other iten
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	X None	al planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
			+
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		ICIVISE DISCE	SOME I SHA
Date	e:2022/4/2	7	
You	r Name: Xinxin	Zhao	
Mar met	nuscript Title: Real-Wor astatic renal cell carcinoma:	ld data on the efficacy and A Multicenter Retrospec	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your naties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to tl med In it	he epidemiology of hyperter dication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/4/	27	
	r Name:Song		
Mar met	nuscript Title: Real-Wo astatic renal cell carcinoma	orld data on the efficacy and	d safety of Pazopanib in IMDC low and intermediate risk ive Cohort Study of Chinese Patients
rela part	ted to the content of your ies whose interests may be	manuscript. "Related" mea e affected by the content of	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	•	it is preferable that you do	•
	following questions apply nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>
med In it	lication, even if that medic	ation is not mentioned in the	all relationships with manufacturers of antihypertensive ne manuscript.  I in this manuscript without time limit. For all other items
		Name all antities with	Specifications/Comments
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initia	I planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

_		_	
Date	:2022/4/2		<del></del>
Your	Name: Xiaofa	an Li	
	•	-	d safety of Pazopanib in IMDC low and intermediate risk
		· ·	ive Cohort Study of Chinese Patients
ivian	uscript number (if known):		
relat parti to tra	ed to the content of your nees whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to th	•	nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup ime frame for disclosure is	•	l in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
1		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time minit for this item.		

Time frame: past 36 months

X\_\_None

\_X\_\_None

X\_\_None

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

3

4

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		icivist biset	OSONE I ONIVI
Date	e:2022/4/2	7	
	r Name: Yuany		
Mar	nuscript Title: Real-Wor	ld data on the efficacy an	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):		
rela <sup>.</sup> part to tr	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the current
to th	he epidemiology of hyperter dication, even if that medica	nsion, you should declare tion is not mentioned in t	·
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items
		A. II	0 15 11 10
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		<u> </u>
	No time limit for this item.		
			+
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		ICIVISE DISCE	SORE FORM
Date	e:2022/4/2	7	
You	r Name: Guoha	ai Shi	
Mar	nuscript Title: Real-Wor	rld data on the efficacy an	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t	o the author's relationship	ps/activities/interests as they relate to the current
to tl med In it	he epidemiology of hyperter dication, even if that medica	nsion, you should declare ition is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other item
tile	time traine for disclosure is	the past 30 months.	
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

		ICIVISE DISCE	SOME I SKINI
Date	e:2022/4/2	7	
You	r Name: Hailia	ng Zhang	
Mar	nuscript Title: Real-Wor	ld data on the efficacy an	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Mar	nuscript number (if known):	·	
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertaing all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other item
		Name of the state of the	Constitution (Comments
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	X None	ar planning of the work
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	
_	any entity (if not indicated		
	in item #1 above).		†

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	X None	
Ŭ			
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/4/2	7	
metasta	atic renal cell carcinoma:	A Multicenter Retrospec	d safety of Pazopanib in IMDC low and intermediate risk tive Cohort Study of Chinese Patients
Manusc	ript number (if known):		
related parties v to trans	to the content of your m whose interests may be parency and does not no	nanuscript. "Related" mea affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript about whether to list a so.
	owing questions apply to ript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to the e medicat In item	pidemiology of hyperter tion, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as needed)	institution)
		Time frame: Since the initia	al planning of the work
1 All	support for the present	X None	
	inuscript (e.g., funding,		
	ovision of study materials,		
-	edical writing, article		
	ocessing charges, etc.)		
	time limit for this item.		
		Time from a second	t 2C months
2 0		Time frame: pas	L 36 MONTHS
	ants or contracts from	XNone	
	y entity (if not indicated		
in i	tem #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	X None	
Ŭ			
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:_	2022/4/2	2.7	
Your N	Name: Dingv	vei Ye	<del></del>
			d safety of Pazopanib in IMDC low and intermediate risk
		•	tive Cohort Study of Chinese Patients
wanu	script number (if known):		<del></del>
relate partie to tra	d to the content of your r s whose interests may be nsparency and does not n	nanuscript. "Related" mea affected by the content o	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	ollowing questions apply t script only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
medic In iten	ation, even if that medica	ntion is not mentioned in the port for the work reported	all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other iten  Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
	All support for the present	XNone	
	nanuscript (e.g., funding, provision of study materials,		
-	nedical writing, article		
	processing charges, etc.)		
	No time limit for this item.		+
			+
		Time frame: pas	t 36 months
2 6	Grants or contracts from	X None	
а	ny entity (if not indicated		
ir	n item #1 above).		

Royalties or licenses

Consulting fees

4

\_X\_\_None

		T	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	X None	
Ŭ			
	,		
7	Support for attending	X None	
,	meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement: